TLSD team operates with cross functional expertise to drive corporate success. Aligning closely with stakeholders across the entire life sciences eco-system and value chain. The team conduct scientific due diligence and publish analyst research, engaging with financial markets (public and private) for access to capital and price discovery in a strong evidence-based approach.
We work with clients to structure deals as well as strategically plan mergers & acquisitions, commercialisation through to industry access. Enabling corporate growth, divestments and or co-creation of ideas. Which can involve repurposing, reverse innovation, reprofiling or developing unique ideas or novel strategies where we can create value and generate accretive options for our corporate and fund clients.
Given our preferred hands on approach, we base our business model on the rationale of six degrees, leveraging our capabilities, utilising the global interconnected world we now live in, to easily reach out within regulatory constraints and without geographical limitations - from the Earths meridian and the heart of London’s medical corridor, we have a network that gives us maximum capabilities with minimal effort to seek and find the best global highly disruptive technologies that fit with 21st Century ideas
Alia Minhas MSc (Oxon) MBA ACSI
Chief Executive Officer
Senior Manager Employed
Ms. Minhas is Director and co-founder of The Life Sciences Division an Investment bank. Alia worked as a buy side equity analyst and associate director in the biotech sector at Mulier Capital, an Investment bank and Investment management firm that specialised in gene therapies.
Prior to establishing and funding a number of life sciences private equity backed businesses, executing on mergers, acquisitions and divestments. Alia’s formative banking career was at Lloyds Banking Group and Scottish Widows Investment Partnership. Mainly working within Wholesale and International Banking.
In her last role at Lloyds, Alia worked within Group Finance as a senior strategy and financial analyst and was involved in a multibillion-pound transformation project. Ms Minhas continues to serve as a Director or Non-executive Director of a number of life science companies.
Dr Navid Malik PhD MSc MBA ACSI
Head of Research and Executive Director
Senior Manager Employed
Navid is an award-winning stock picking analyst, (Starmine and Extel Rated) recognized Internationally for his work in the biotech sector.
Navid began his career at Williams de Broe – now part of the ING group, before moving to Collin Stewart, later as a partner at Matrix Corporate capital he won multiple awards in the sector.
Dr Malik headed up a number of smaller mid-cap broking firm healthcare franchises where he focused on marketing deals before co-founding The Life Sciences Division.
Two Starmine Awards: Across Europe for stock picking pharmaceuticals and for healthcare UK & Eire (2011)
Navid has lead some of the largest European IPOs in the biotech sector, successfully floating companies onto the London Stock Exchange AIM market, as well as raising billions of dollars of capital. Dr Malik is an extel rated research analyst and continues to write extensive corporate and detailed thematic research on industry.
Dr Malik continues to serve as a Director or Non-executive Director of a number of life science companies.
Dr Christina (Ena) Bromley PhD MSc
Director REGULATORY AND BIO-ANALYTICS
Dr. Bromley is a statistical geneticist, genetic epidemiologist, visionary and analytical expert. Ena supports the team in building corporate growth and avoiding clinical risk through actionable decision making, scientific knowledge, regulatory and bio-analytic insight, as well as thought leadership.
Ena has been contributing to international regulatory agencies along with biotech and large pharmaceutical companies for 26 years. She has provided her expert opinion in the design, analysis and interpretation of complex data. This includes representing companies towards regulatory approval for vaccines, targeted therapeutics, drug discovery and medical devices.
Dr. Bromley co-founded BioStat Solutions, Inc (BSSI) in 2001 the company was acquired by PharmaLex in September of 2020 facilitating its expansion of analytical services internationally.
Dr. Bromley serves the Bayesian Biostatistics Meeting and is co-chair for MBSW (Midwest Biopharmaceutical Statistics Workshop). Dr. Bromley also serves on various data safety monitoring committees.
Ena utilizes her knowledge across various therapeutic areas as well as her network of key opinion leaders (KOL’s) to bridge the communication gap between scientific expertise and investment opportunities. Ena lives in the USA with her family.
Prof. Ashley George PhD FRSC
Ashley works with the team across corporate broking and advisory, with a focus on transactions that are research led ideas for strategic corporate growth, mergers, acquisitions, divestments and co-creation.
Prof George is a visiting lecturer at UCL and serves as treasurer to Pistoia alliance a not for profit organization as well as continues to serve as a Director or Non-executive Director of a number of Life Sciences companies.
Ashley has over 26 years of experience in the life sciences industry most recently as a Global Executive at GlaxoSmithKline (GSK) and served as Global Head of Centre of Excellence for Innovation and Consumerisation.
Ashley is an award winner of multiple disruptive digital and transformative technologies in the healthcare space including GSK’S MyAsthma digital App obtaining both EU CE - mark and FDA 510k approval.
Najma Pirzada MSc MA ACSI
DIRECTOR- HEAD OF EQUITY CAPITAL MARKETS
Najma serves as Head of Equity Capital Markets currently working with bulge bracket global financial institutions primarily focussed on public and private markets transactions. As well as oversight of corporate finance, economics and policy work supporting cross collaborative thought leadership in ‘New Healthcare Thinking’ at The Life Sciences Division.
She has more than 25 years’ experience across capital markets, economic and policy advisory, and in digital communications as an entrepreneur who co-founded a multi-media news platform. She holds a MSc in Economics (with Distinction) from the University of London and a MA in International Affairs from Columbia University, New York. She graduated from the London School of Economics with a BSc (honours) in Economics. And is an associate member of the Chartered Institute of Securities and Investment.
Najma has lived and worked in Europe, Asia and USA. Clients include governments, regulatory authorities, sovereign wealth funds, corporate and institutional clients (pensions/asset managers), senior public officials, donor agencies, non-governmental organizations, research organizations, and think tanks.
Her experience in capital markets was gained at Standard Chartered Bank where she was an Executive Director and before then as Vice President at Lehman Brothers. She worked on key client accounts and developing comprehensive hedging tools. Early in her career she worked on M&A deals in the pharma & biotechnology sector, including Novartis, and Astra Zeneca, Syngenta and Monsanto. As well as anti-monopoly policy work at NERA, the economic consulting subsidiary of Marsh & McLennan Companies, Inc.
Najma has been Executive Director and Managing Editor of Global Village Space Publications. A multi-media news company active in digital comms and social media with millions of followers. She is a trustee on the Indus Heritage Trust, an economic livelihood project for women artisans. She is a member of Track II Dialogues working on Afghanistan/Pakistan/India.
She has served on the Lahore Stock Exchange as a board director and maintains a number of director or non-executive board directorships. She is an entrepreneur in residence with an active portfolio of early development stage companies.
Robert Harrington-Jones LLB (Hons)
Director Head of Sales
Mr Harrington-Jones has over 26 years investment banking experience, across UK and Asia. Currently supporting our clients as Head of Sales. He has developed extensive relationships across bulge bracket financial institutions internationally.
Robert joins us after almost nine years at SWS Securities in Hong Kong where he ran the Asia, US and European teams as Head of Institutional Sales. Prior to this he worked as an equity sales manager at Mirae Assets Global Investments Co, one of the largest Korean asset management firms.
He was an executive director at the investment bank, RBS Greater China, where his equities desk regularly outperformed. His team focused on selling research to Taiwan, Hong Kong, Singapore into long only and hedge funds, and other institutions Robert moved to the sell side in 2001, as a north Asian equity specialist, and held senior roles at leading local firms like Yuanta Securities in Taiwan which had a high volume and high margin trading business, consistently a top Asian contributor.
His career began on the buy side spending 5 years in London working on trading desks and then in research at Thornton’s Asset Management and City of London Investment Management. Where he also served as deputy money laundering officer. Both these firms were successful
emerging markets equity investors with multibillion AUM.
Mr Harrington-Jones has served as a board member at Springboard Capital, a Hong Kong based Greater China long/short equity fund. And is an angel investor in a number of biotech companies.
Robert is a proficient business level Mandarin speaker. He is affiliated to the Chartered Institute for Securities and Investment in London.
Resitha Airey BSc (Hons) CPE, ABPI
Director Corporate Advisory
Ms Airey has a clear focus on corporate clients. Corporate advisory and value accretion through evidence-based medicine, real world outcomes, commercialisation and industry market access.
Resitha is active across various life sciences industry and advisory boards with key opinion leaders, healthcare payors, and patient advocacy groups.
Resitha has over 26 years of experience working in large pharma, most recently within the Novartis Group, at Alcon as Scientific Operations Executive leading the global ophthalmology real world outcomes study on 500,000 patients.
Ms Airey began her career at MSD (Merck, Sharpe and Dohme), then moved to Pfizer to work within the cardiovascular team on sales of Lipitor into hospitals.
Resitha is an award winner at Novartis and Alcon, most recently for excellence - Communiqué redefining Lucentis marketing and has won multiple awards for creating and implementing digital technology platforms.
Ms Airey continues to serve as Director or Non-executive Director of a number of life sciences companies.
Prof Dr Ning Qu MD PhD
Medical and Scientific Director
Ning conducts due diligence with the rigor of scientific and clinical methodology but with a translational read across to commercialisation of prospective ideas, reverse innovation and co-creation. Having invested in multiple private companies across Europe, he has a buy side approach.
Dr Qu occasionally works on the most demanding cases in Cardiothoracic Surgery in the Netherlands where he has lived for 25 years and gained his PhD from Groningen University in Lung Transplantation Immunology. Dr Qu is currently holding two (visiting) Professor positions in Cardio Thoracic Surgery and Translational Medicine.
Ning is the founder and Chairman of SEMICO a Netherlands based foundation in the Healthy Ageing Campus at the UMCG Groningen. It is established to further Sino-EU medical innovation and cooperation, Ning sits on the investment committee.
Dr Qu continues to serve as a Director or Non-executive Director of a number of life science companies.
Prof. Dr. Gene Olinger PhD MBA
Research & SCIENTIFIC Advisor
Gene is a scientist with over 20 years of experience leading complex projects that aim to solve long standing problems within clinical diagnostics, therapeutics, and immunology. He is considered a leading authority for complex in-vitro and in-vivo studies, in BSL-3/BSL-4 laboratories, where he has focused on the development of vaccines and countermeasures to emerging pathogens and biological threats. He is now focused on companies and programs with a special interest in synthetic biotechnology, bioengineering, and artificial intelligence.
Dr. Olinger is a proven thought leader in infectious diseases, bio-surveillance, public health and medical intervention development, evidenced by 3 patents, and over 100 peer-reviewed published manuscripts, abstracts, and reviews.
Prof Olinger is a subject matter expert in immunology, pathogenesis, host-pathogen interactions, virology, and vaccinology holding two professorships: Professor at the College of Biosciences at Kansas City University of Medicine. And an Adjunct Associate Professor at Boston University - Boston University Medical Center, Department of Medicine, Section of Infectious Disease.
Dr Olinger has served in a NGO in Maryland since 2013 as its Lead Scientist for the Life Science PI & SME capabilities.
Gene lives in the USA with his family and continues to serve as a Director or Non-executive Director of a number of life science companies.
Dr Andrea Rosati MSc PhD
DIRECTOR, HEAD OF AGRO-TECHNOLOGIES
Dr Rosati has over 30 years’ experience in animal genetics, livestock, crop, agricultural technologies, and aquaculture. He leads the European Federation of Animal Science and the World Association for Animal Production. Andrea was the co-founder of four scientific journals where he now serves on the management boards. An internationally recognised lecturer on animal production, sustainability, and agricultural development.
He began his career as an Agricultural Scientist having graduated from Università degli Studi di Perugia followed with a M.Sc. Animal Genetics and a Ph.D. in Animal Genetics, Statistical analysis, and Biometry at University of Nebraska - Lincoln (USA). Andrea initially worked at the Italian Animal Breeders Organization with national scale responsibilities evaluating performance and genetics of livestock. Before becoming the CEO of the Italian Animal Genetics Laboratory and CEO of the International Committee for Animal Recording, establishing world standards (ICAR) for animal identification, performance, and genetic evaluation.
During his career Andrea gained widespread experience of cooperation with both government and non-government international organizations as well as commercial and early-stage research companies. He provides expert consultancy to improve efficiency and genetic improvement in large animal farming companies across the world.
Dr Rosati has been a partner to more than 20 research projects funded by the European Union. He is a distinguished scientist and co-author of over 50 peer reviewed papers. He is co-author of two technical books on animal husbandry. Andrea maintains a few director or non-executive board directorships.
In 2018 Dr Rosati was Knighted by the French Order of Agricultural Merit for exceptional services to Agriculture.